Effects of Pimobendan and its active metabolite, UD-CG 212 Cl, on Ca2+-activated K+ channels in vascular smooth-muscle cells

Journal of Cardiovascular Pharmacology

Volumn 30, Issue 6, 1997, Pages 739-743

  Chen, Chun He ^a   Nakaya, Yutaka ^a   Minami, Kazushi ^a   Kubo, Masahiro ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Ca2+ (i); Ca2+ sensitivity; K(Ca) channel; Pimobendan; UD CG 212 Cl

Indexed keywords

N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; O NORPIMOBENDAN; PIMOBENDAN; POTASSIUM CHANNEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HYPERPOLARIZATION; INOTROPISM; MUSCLE FIBER CULTURE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SECOND MESSENGER; SMOOTH MUSCLE FIBER; SWINE; VASODILATATION;

ANIMALS; CALCIUM; CARDIOTONIC AGENTS; CORONARY VESSELS; DRUG INTERACTIONS; ENZYME INHIBITORS; HEART; ISOQUINOLINES; MUSCLE, SMOOTH, VASCULAR; POTASSIUM CHANNELS; PYRIDAZINES; SULFONAMIDES; SWINE; VASODILATION;

EID: 0031414832     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199712000-00007     Document Type: Article

References (31)

1. Diederen W, Dammgen J, Kadatz R. Cardiovascular profile of UD-CG 115, a new orally and long acting cardiotonic compound, not related to β-mimetics or cardiac glycosides. Naunyn Schmiedebergs Arch Pharmacol 1982;321:141-6.
2. van Meel JC, Diederen W. Hemodynamic profile of the cardiotonic agent pimobendan. J Cardiovasc Pharmacol 1989;14(suppl II):S1-6.
3. Duncker DJ, van Dalen FJ, Hartog JM, et al. Usefulness of pimobendan in the treatment of heart failure. Arzneimittelforschung 1986;36:1740-4.
4. Walter M, Liebens I, Goethals H, Renard M, Dresse A, Bernard R. Pimobendan (UD-CG 115 BS) in the treatment of severe congestive heart failure: an acute haemodynamic crossover and double-blind study with two different doses. Br J Clin Pharmacol 1988; 25:323-9.
5. Baumann G, Ningel K, Permanetter B. Clinical efficacy of pimobendan (UD-CG 115 BS) in patients with chronic congestive heart failure. J Cardiovasc Pharmacol 1989;14(suppl II):S23-30.
6. Honerjager P, Heiss A, Schafer-Korting M, Schonsteiner G, Reiter M. UD-CG 115-A cardiotonic pyridazinone which elevates cyclic AMP and prolongs the action potential in guinea-pig papillary muscle. Naunyn Schmiedebergs Arch Pharmacol 1984;325:259-69.
7. Scholz H, Meyer W. Phosphodiesterase inhibiting properties of newer inotropic agents. Circulation 1986;73(suppl III):99-108.
8. Ruegg J, Pfitzer G, Eubler D, Zeugner C. Effect on contractility of skinned fibres from mammalian heart and smooth muscle by a new benzimidazole derivative 4,5-dihydro-6-[2-(methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-3(2H)- phyidazolinone. Arzneimittelforschung 1984;34:1736-8.
9. Fujimoto S. Effects of pimobendan, its active metabolite UD-CG 212 Cl, and milrinone on isolated blood vessels. Eur J Pharmacol 1994;265:159-66.
10. Westfall MV, Wahler GM, Fujino K, Solaro RJ. Electrophysiological actions of the pimobendan metabolite, UG-CD 212 Cl, in guinea pig myocardium. J Pharmacol Exp Ther 1991;260:58-63.
11. + channel of vascular smooth muscle cells. Life Sci 1995;56:291-8.
12. Ohnishi A, Ishizaki T. Pharmacokinetic profile of OPC-8212 in humans: a new, nonglycosidic, inotropic agent. J Clin Pharmacol 1988;28:719-26.
13. Nelson MT, Patlak JB, Worley JF, Atanded NB. Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone. Am J Physiol 1990;259(Cell Physiol 28):C3-18.
14. Toro L, Vaca L, Stefani E. Calcium-activated potassium channels from coronary smooth muscle reconstituted in lipid bilayers. Am J Physiol 1991;260 (Heart Circ Physiol):H1779-89.
15. Sadoshima J, Akaike N, Kanaide H, Nakamura M. Cyclic AMP modulates Ca-activated K channel in cultured smooth muscle cells of rat aortas. Am J Physiol 1988;255 (Heart Circ Physiol):H754-9.
16. + channel by cyclic AMP in cultured porcine coronary artery smooth muscle cells. Life Sci 1993;53:1129-35.
17. Ross R. The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol 1971;50:172-86.
18. Fujimoto S, Matsuda T. Effects of pimobendan, a cardiotonic and vasodilating agent with phosphodiesterase inhibiting properties, on isolated arteries and veins of rats. J Pharmacol Exp Ther 1990;252:1304-11.
19. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FG. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 1981;391: 85-100.
20. + channel of cultured porcine coronary artery smooth muscle cells. Biochem Biophys Res Commun 1993;190:263-9.
21. Chijiwa T, Mishima A, Hagiwara M, et al. Inhibition of forskolin-induced neunte outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem 1990;265:5267-72.
22. Bell D, McDermott BJ. Use of the cyclic AMP antagonist, Rp-cAMPS, to distinguish between cyclic AMP-dependent and cyclic AMP-independent contractile responses in rat ventricular cardiomyocytes. J Mol Cell Cardiol 1994;26:1439-48.
23. Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure: mechanisms of action and recent clinical developments. N Engl J Med 1986;314:349-58.
24. Endoh M, Shibasaki T, Satoh H, Norota I, Ishihata A. Different mechanisms involved in the positive inotropic effects of benzimidazole derivative UD-CG 115 BS (pimobendan) and its demethylated metabolite UD-CG 212 Cl in canine ventricular myocardium. J Cardiovasc Pharmacol 1991;17:365-75.
25. Bohm M, Morano I, Pieske B, et al. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ Res 1991;68:689-701.
26. Fujino K, Sperelakis N, Solaro RJ. The positive inotropic effect of pimobendan involves stereospecific increases in the calcium sensitivity of cardiac myofilaments. Circ Res 1988;63:911-22.
27. Verdouw PD, Hartog JM, Duncker DJ, Roth W, Saxena PR. Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. Eur J Pharmacol 1986;126:21-30.
28. Hagemeijer F. Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. Eur Heart J 1993;14:551-66.
29. + channels by novel benzimidazolone. Eur J Pharmacol 1994;251:53-9.
30. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 1995;268(Cell Physiol 37):C799-822.
31. Wilde DW, Lee KS. Outward potassium current in freshly isolated smooth muscle cell of dog coronary arteries. Circ Res 1989; 65: 1718-34.